Business Wire

OH-PROCTER-&-GAMBLE

2.12.2020 10:35:04 CET | Business Wire | Press release

Share
Crest, Oral-B and Blend-a-med Announce the Launch of Their First Ever Recyclable HDPE Toothpaste Tubes in North America and Europe

Today, Procter & Gamble Oral Care unveils its newest packaging innovation across its leading toothpaste brands, Crest, Oral-B and Blend-a-med. This announcement increases the level of recyclability of its toothpaste tubes, as part of the P&G Ambition 2030 commitments of achieving 100% recyclable or reusable packaging.

The leading global oral care brands, Crest and Oral-B, and the European brand Blend-a-med, will start the switch in January 2021 and will continue until full conversion, by 2025.

Toothpaste tubes are used by millions of consumers every day; however, its multi-material construction poses a challenge for recycling facilities around the globe. The solution to this is the HDPE – High-Density Polyethylene – tube, which provides the same product protection as current tubes, and which has been certified by North American and European recycling bodies to be compatible with existing recycling technologies. These HDPE tubes can be recycled where collection programs exist.

For introducing the right solution and making its toothpaste tubes more sustainable, Procter & Gamble is in discussions with several HDPE tube suppliers and has already reached an agreement with Albéa to start using its proprietary Greenleaf Generation 2 tube technology, which enables the tubes to be recyclable wherever collection schemes are active. Greenleaf Generation 2 tubes are recognized by the North American Association of Plastic Recyclers (APR) as well as RecyClass and SUEZ.circpack® in Europe and can be recycled within the existing, effective HDPE bottles recycling stream.

To earn APR recognition, it was demonstrated that the toothpaste tubes could be converted into quality post-consumer HDPE resin, and then reused to make new plastic bottles.

RecyClass is an independent cross-industry platform that assesses material recyclability and provides specific recommendations on how to improve packaging design to fit current recycling technologies in Europe. The platform certifies that Procter & Gamble’s ‘toothpaste tube’ technology is considered to be compatible with HDPE recycling. Moreover, it certifies that both Procter & Gamble’s ‘toothpaste tubes with cap’ product will not have a negative impact on the current European HDPE containers recycling.

“Toothpaste tubes are not largely recyclable today; with the RecyClass certification for Albéa’s Greenleaf Generation 2 technology used by P&G, however, we are on the right track towards increasing both the design for recycling awareness for tubes as well as increasing recycling quality and rates for the HDPE rigids stream in Europe,” said Paolo Glerean, RecyClass Chairman.

In addition, the sortability of the tubes has been successfully tested by SUEZ.circpack® following the RecyClass sorting protocol, confirming that the tubes will flow into the correct stream and be recycled with the HDPE materials.

“Accurate sorting is an essential step to ensure recycling. That is why SUEZ.circpack® performed sorting tests in a fully operational sorting facility in Germany. The facility and the technologies in place are very common for the European recycling industry. The results showed that the packaging could be correctly sorted into the HDPE material flow. The recognition of the plastic with Near InfraRed (NIR) technology was accurate and consistent,” said Vincent Mooij, Head of SUEZ.circpack® .

“P&G Oral Care started our sustainability journey many years back and continue to reduce our footprint. To drive a more circular supply chain, all of our production sites globally are qualified as sending zero manufacturing waste to landfill, and our sites across the United States, Canada, and Europe purchase 100% renewable electricity,” stated Steve Bishop, P&G Health Care Chief Executive Officer. “There is much yet to be done; however, we are proud of the steps we are taking with our leading brands, Crest in North America, and Oral B and Blend-a-med in Europe, to achieve recyclable tubes in the years ahead.”

Virginie Helias, P&G’s Chief Sustainability Officer added: “We have committed to enable and inspire responsible consumption through innovation on our product and packaging. Our leading oral care brands touch millions of people around the world. This new packaging innovation will contribute to making the toothpaste tubes recyclable at scale in existing recycling streams, hence reducing our footprint and striving for circular solutions. It’s no longer about if or what we can do, but how quickly we can do it.”

About P&G:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com  for the latest news and information about P&G and its brands.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye